TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01707069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals.
Study: NCT02166840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stent (7-10Fr)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self Expanding Metal Stent
Study: NCT05782920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non cross-linked hyaluronic acid
Description: HA filling is a known modality for rejuvenation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: topical HA gel
Description: the standard treatment of vaginal atrophy and dryness
Study: NCT03238235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: suspension of Givinostat (10 mg/mL)
Study: NCT02420977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelvic DCFPyL PET-MRI fusion or PET/MRI
Description: * Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months
Study: NCT00287638

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no CPAP
Study: NCT04424485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy (TT)
Description: Standard TT procedure for thyroid carcinoma, for both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy (TT)
Description: Standard TT procedure for thyroid carcinoma, for both groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central lymph node dissection (CLND)
Description: Standard CLND for thyroid carcinoma, for both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central lymph node dissection (CLND)
Description: Standard CLND for thyroid carcinoma, for both groups

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) bopsy
Description: Intrathyroidal injection of ICG for SL biopsy, for only experimental group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification of parathyroid glands (PGs)
Description: Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
Study: NCT04785183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin drops
Description: Melatonin oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral 5% glucose
Study: NCT01125202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCT-based behavioral intervention
Description: Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
Study: NCT02775617

Intervention type: DRUG
Group type: OTHER
Intervention: Ivermectin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.

Intervention type: DRUG
Group type: OTHER
Intervention: Ivermectin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.

Intervention type: DRUG
Group type: OTHER
Intervention: Permethrin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.

Intervention type: DRUG
Group type: OTHER
Intervention: Permethrin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
Study: NCT00875641

Intervention type: OTHER
Intervention: Health Insurance Database
Description: Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.

Intervention type: OTHER
Intervention: Health Insurance Database
Description: Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.

Intervention type: OTHER
Intervention: Health Insurance Database
Description: Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
Study: NCT04198961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opioid prescribing
Description: Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
Study: NCT01857453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatine
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
Study: NCT02235610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLP Group
Description: EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
Study: NCT02335268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Plate / romiplostim
Description: medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Plate / romiplostim
Description: medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Plate / romiplostim
Description: medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
Study: NCT01441778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSS nasal irrigation salt
Description: nasal irrigation twice daily for 4 weeks period
Study: NCT03238235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: suspension manufactured to mimic Givinostat
Study: NCT00863928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belladonna 16.2 mg and opium 60 mg suppository
Description: belladonna 16.2 mg and opium 60 mg suppository
Study: NCT06400238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study: NCT01441778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHS nasal irrigation salt
Description: nasal irrigation twice daily for 4 weeks period
Study: NCT01505075

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation
Description: 40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
Study: NCT04827225

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
Study: NCT04390464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Regular standard of care for COVID-19 patients
Study: NCT06400238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03900884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Study: NCT01055782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoguide
Description: Use of endoguide to facilitate completion of endoscopy
Study: NCT04612595

Intervention type: OTHER
Intervention: serum urea nitrogen to creatinine ratio
Description: According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO
Study: NCT01096602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC AML Vaccine
Description: Group 1: 2-3 doses of the vaccine at 4 week intervals
Study: NCT03311945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (1200 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (300 mg QD)
Study: NCT04666753

Intervention type: DIETARY_SUPPLEMENT
Intervention: ImmunoFormulation
Description: The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
Study: NCT02902133

Intervention type: DRUG
Group type: OTHER
Intervention: Acetazolamide
Description: Acetazolamide 500 mg by mouth twice per day for 5 days
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT00769587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT01941069

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friends for Life
Description: Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
Study: NCT04612595

Intervention type: OTHER
Intervention: serum urea nitrogen to creatinine ratio
Description: According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.

Intervention type: OTHER
Intervention: serum urea nitrogen to creatinine ratio
Description: According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
Study: NCT01454362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Inhalation of nicotine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Inhalation of nicotine.
Study: NCT00534755

Intervention type: OTHER
Group type: OTHER
Intervention: Breast Cancer database
Description: prospective breast cancer database
Study: NCT04307979

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High-fat coffee
Description: A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat coffee
Description: A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black coffee
Description: A regular black coffee with no added caloric content.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04307979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black coffee
Description: A regular black coffee with no added caloric content.
Study: NCT04259281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide
Study: NCT04340193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study: NCT05092932

Intervention type: OTHER
Intervention: Normal Foot Force
Description: LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
Study: NCT04173845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianqi Pingchan Granule
Description: Tianqi Pingchan Granule are given twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tianqi Pingchan Granule Placebo
Description: Tianqi Pingchan Granule Placebo
Study: NCT01313598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187
Description: continuous IV infusion
Study: NCT04253821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index
Description: The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index
Description: The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
Study: NCT04623723

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )
Description: Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (FS-407, EMS® Piezon, Switzerland)
Description: Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)